due to the lack of new therapies to combat this form of lung cancer. SCLC is characterized by neuroendocrine differentiation, a high growth fraction, rapid doubling time and early establishment of widespread metastatic lesions. About a third of patients present with limited stage disease. Most patients present with extensive-stage disease. These stages impact available therapeutic regiments, with limited stage disease treated with chemotherapy and radiation and extensive stage disease treated with chemotherapy alone.

**[0004]** Patients with SCLC have high rates of response to first line chemotherapy, which includes etoposide and cisplatin, and also to radiation therapy, but invariably quickly relapse. There are approved therapies for relapsed disease but chemoresistance develops for which no therapeutic options are available. Prognosis in the relapsed refractory setting is extremely poor, with rapid disease progression and short median survival of less than six months once the patient is on the third line of treatment. Patients with extensive stage SCLC (ES-SCLC) develop drug resistance and die as a result of disease at a median time of 10 to 12 months from diagnosis

**[0005]** AMG 757 (also known as tarlatamab) is a bispecific T-cell engager (BiTE®) molecule targeting DLL3 on cancer cells and CD3 on T-cells. It is developed for the treatment of DLL3-positive cancers such as SCLC and neuroendocrine prostate cancer (NEPC) and is being evaluated in clinical trials.

**[0006]** Efforts have been made to develop therapies for the treatment of DLL3-positive such as SCLC, but overall survival remains poor. There is an unmet medical need for the development of therapies for the treatment of DLL3 positive cancers such as SCLC.

## SUMMARY

**[0006a]** In one aspect, the present disclosure relates to use of an anti-DLL3 agent comprising the amino acid sequence of SEQ ID NOs: 13 and 23 in the manufacture of a medicament for treating DLL3-positive cancer, wherein the anti-DLL3 agent is to be administered at a dose of from 10 mg to 100 mg twice every three weeks.

**[0006b]** In another aspect, the present disclosure related to use of an anti-DLL3 agent comprising the amino acid sequence of SEQ ID NOs: 13 and 23 in the manufacture of a medicament for treating DLL3-positive cancer, wherein the anti-DLL3 agent is to be administered at a dose of from 20 mg to 200 mg once every three weeks.

**[0006c]** In another aspect, the present disclosure related to Use of an anti-DLL3 agent comprising the amino acid sequence of SEQ ID NOs: 13 and 23 in the manufacture of a medicament for treating DLL3-positive cancer, wherein the anti-DLL3 agent is to be administered according to the following regimen: a) the anti-DLL3 agent is to be administered in a first cycle wherein (i) the anti-DLL3 agent is to be administered at a dose of from 1 mg to 200 mg by continuous intravenous infusion over a period of 2 days to 7 days, and (ii) after the continuous intravenous infusion, the anti-DLL3 agent is to be administered by a bolus intravenous infusion on day 8, day 15, or both day 8 and day 15, and b) the anti-DLL3 agent is to be administered according to any one of i) to iii) below:

i) one or more subsequent doses of the anti-DLL3 agent is to be administered at a dose of from 10 mg to 100 mg starting on day 29 and once every two weeks thereafter; ii) one or more subsequent doses of the anti-DLL3 agent is to be administered at a dose of from 10 mg to 100 mg starting on day 22 and twice every three weeks thereafter; and iii) one or more subsequent doses of the anti-DLL3 agent is to be administered at a dose of from 20 mg to 200 mg starting on day 22 and thereafter once every three weeks.

**[0006d]** In another aspect, the present disclosure related to use of an anti-DLL3 agent comprising the amino acid sequence of SEQ ID NOs: 13 and 23 and an anti-PD-L1 antibody in the manufacture of a medicament for combination therapy for treating DLL3-positive cancer, wherein the anti-DLL3 agent is to be administered according to any one of a) to c) below: a) the anti-DLL3 agent is to be administered at a dose of from 10 mg to 100 mg once every two weeks; b) the anti-DLL3 agent is to be administered at a dose of from 10 mg to 100 mg twice every three weeks; and c) the anti-DLL3 agent is to be administered at a dose of from 20 mg to 200 mg once every three weeks; optionally wherein the medicament is to be administered in conjunction with one or more therapeutic agents.

**[0006e]** In another aspect, the present disclosure related to use of an anti-DLL3 agent comprising the amino acid sequence of SEQ ID NOs: 13 and 23, and an alkylating agent in the manufacture of a medicament for combination therapy for treating DLL3-positive cancer, wherein the anti-DLL3 agent is to be administered to the subject at a dose of from 10 mg to 200 mg once every three weeks.

**[0006f]** In another aspect, the present disclosure related to use of an anti-DLL3 agent comprising the amino acid sequence of SEQ ID NOs: 13 and 23, and an alkylating agent in the manufacture of a medicament for combination therapy for treating DLL3-positive cancer, wherein the anti-DLL3 agent is to be administered to the subject according to the following: a first dose of 0 mg or 1 mg on day 1, a second dose of from 10 mg to 100 mg on day 8, a third dose of from 10 mg to 200 mg on day 15, and one or more subsequent doses of from 10 mg to 200 mg starting on day 22 and once every three weeks thereafter.

**[0006g]** In another aspect, the present disclosure related to use of an anti-DLL3 agent comprising the amino acid sequence of SEQ ID NOs: 13 and 23 in the manufacture of a first medicament and use of an anti-PD-L1 antibody in the manufacture of a second medicament, wherein the first and second medicament are to be used in combination therapy for treating DLL3-positve cancer, wherein the anti-DLL3 agent is to be administered according to any one of a) to c) below: a) the anti-DLL3 agent at is to be administered a dose of from 10 mg to 100 mg once every two weeks; b) the anti-DLL3 agent is to be administered at a dose of from 10 mg to 100 mg twice every three weeks; and c) the anti-DLL3 agent is to be administered at a dose of from 20 mg to 200 mg once every three weeks; optionally wherein the medicaments are to be administered in conjunction with one or more chemotherapeutic agents.

**[0006h]** In another aspect, the present disclosure related to use of an anti-DLL3 agent comprising the amino acid sequence of SEQ ID NOs: 13 and 23 in the manufacture of a medicament for use in combinatorial therapy for treating DLL3-positive cancer, wherein the medicament is to be administered in combination with an anti-PD-L1 antibody to a subject in need thereof, wherein the anti-DLL3 agent is to be administered according to any one of a) to c) below:

a) the anti-DLL3 agent at is to be administered a dose of from 10 mg to 100 mg once every two weeks; b) the anti-DLL3 agent is to be administered at a dose of from 10 mg to 100 mg twice every three weeks; and c) the anti-DLL3 agent is to be administered at a dose of from 20 mg to 200 mg once every three weeks; optionally wherein the composition is to be administered in conjunction with one or more chemotherapeutic agents.

**[0006i]** In another aspect, the present disclosure related to use of an anti-PD-L1 antibody in the manufacture of a medicament for use in combinatorial therapy for treating DLL3-positive cancer, wherein the medicament is to be administered in combination with an anti-DLL3 agent comprising the amino acid sequence of SEQ ID NOs: 13 and 23, wherein the anti-DLL3 agent is to be administered according to any one of a) to c) below: a) the anti-DLL3 agent is to be administered at a dose of from 10 mg to 100 mg once every two weeks; b) the anti-DLL3 agent is to be administered at a dose of from 10 mg to 100 mg twice every three weeks; and c) the anti-DLL3 agent is to be administered at a dose of from 20 mg to 200 mg once every three weeks; optionally wherein the medicament is to be administered in conjunction with one or more chemotherapeutic agents.

**[0006j]** In another aspect, the present disclosure related to use of an anti-DLL3 agent comprising the amino acid sequence of SEQ ID NOs: 13 and 23 in the manufacture of a first medicament and use of an alkylating agent in the manufacture of a second medicament, wherein the first and second medicament are to be used in combination therapy for treating DLL3-positve cancer, wherein the anti-DLL3 agent is to be administered to the subject at a dose of from 10 mg to 200 mg once every three weeks.

**[0006k]** In another aspect, the present disclosure related to use of an anti-DLL3 agent comprising the amino acid sequence of SEQ ID NOs: 13 and 23 in the manufacture of a medicament for use in combinatorial therapy for treating DLL3-positive cancer, wherein the medicament is to be administered in combination with an alkylating agent to a subject in need thereof, wherein the anti-DLL3 agent is to be administered to the subject at a dose of from 10 mg to 200 mg once every three weeks.

**[0006l]** In another aspect, the present disclosure related to use of an alkylating agent in the manufacture of a medicament for use in combinatorial therapy for treating DLL3-positive cancer, wherein the medicament is to be administered in combination with an anti-DLL3 agent comprising the amino acid sequence of SEQ ID NOs: 13 and 23 to a subject in need thereof, wherein the anti-DLL3 agent is to be administered to the subject at a dose of from 10 mg to 200 mg once every three weeks.

**[0006m]** In another aspect, the present disclosure related to use of an anti-DLL3 agent comprising the amino acid sequence of SEQ ID NOs: 13 and 23 in the manufacture of a first medicament and use of an alkylating agent in the manufacture of a second medicament, wherein the first and second medicament are to be used in combination therapy for treating DLL3-positve cancer, wherein the anti-DLL3 agent is to be administered to the subject according to the following: a first dose of 0 mg or 1 mg on day 1, a second dose of from 10 mg to 100 mg on day 8, a third dose of from 10 mg to 200 mg on day 15, and one or more subsequent doses of from 10 mg to 200 mg starting on day 22 and once every three weeks thereafter.

**[0006n]** In another aspect, the present disclosure related to use of an anti-DLL3 agent comprising the amino acid sequence of SEQ ID NOs: 13 and 23 in the manufacture of a medicament for use in combinatorial therapy, wherein the medicament is to be administered in combination with an alkylating agent to a subject in need thereof, wherein the anti-DLL3 agent is to be administered to the subject according to the following: a first dose of 0 mg or 1 mg on day 1, a second dose of from 10 mg to 100 mg on day 8, a third dose of from 10 mg to 200 mg on day 15, and one or more subsequent doses of from 10 mg to 200 mg starting on day 22 and once every three weeks thereafter.

**[0007] [0006o]** In another aspect, the present disclosure related to use of an alkylating agent in the manufacture of a medicament for use in combinatorial therapy for treating DLL3-positive cancer, wherein the medicament is to be administered in combination with an anti-DLL3 agent comprising the amino acid sequence of SEQ ID NOs: 13 and 23 to a subject in need thereof, wherein the anti-DLL3 agent is to be administered to the subject according to the following: a first dose of 0 mg or 1 mg on day 1, a second dose of from 10 mg to 100 mg on day 8, a third dose of from 10 mg to 200 mg on day 15, and one or more subsequent doses of from 10 mg to 200 mg starting on day 22 and once every three weeks thereafter. Based on the disclosure provided herein, those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific examples of the disclosure described herein. Such equivalents are intended to be encompassed by the following examples (E).

**[0008]** E1: A method of treating DLL3-positive cancer, comprising administering to a subject in need thereof an anti-DLL3 agent, wherein the anti-DLL3 agent is administered at a dose of from 10 mg to 100 mg weeks twice every three weeks.

**[0009]** E2: A method of treating DLL3-positive cancer, comprising administering to a subject in need thereof an anti-DLL3 agent, wherein the anti-DLL3 agent is administered at a dose of from 20 mg to 200 mg once every three weeks.

# CLAIMS

What is claimed:

1. Use of an anti-DLL3 agent comprising the amino acid sequence of SEQ ID NOs: 13 and 23 in the manufacture of a medicament for treating DLL3-positive cancer, wherein the anti-DLL3 agent is to be administered at a dose of from 10 mg to 100 mg twice every three weeks.

2. The use of claim 1, wherein the anti-DLL3 agent is to be administered at a dose of 10 mg, 30 mg, or 100 mg, twice every three weeks.

3. The use of claim 1 or claim 2, wherein the anti-DLL3 agent is to be administered on day 1 and day 8 of a 21-day cycle.

4. Use of an anti-DLL3 agent comprising the amino acid sequence of SEQ ID NOs: 13 and 23 in the manufacture of a medicament for treating DLL3-positive cancer, wherein the anti-DLL3 agent is to be administered at a dose of from 20 mg to 200 mg once every three weeks.

5. The use of claim 4, wherein the anti-DLL3 agent is to be administered at a dose of from 20 mg to 100 mg once every three weeks.

6. The use of claim 4, wherein the anti-DLL3 agent is to be administered at a dose of from 100 mg to 200 mg once every three weeks.

7. The use of any one of claims 4-6, wherein the anti-DLL3 agent is to be administered at a dose of 20 mg, 60 mg, 100 mg, or 200 mg.

8. The use of any one of claims 4-7, wherein the anti-DLL3 agent is to be administered on day one of a 21-day cycle.

9. Use of an anti-DLL3 agent comprising the amino acid sequence of SEQ ID NOs: 13 and 23 in the manufacture of a medicament for treating DLL3-positive cancer, wherein the anti-DLL3 agent is to be administered according to the following regimen:

a) the anti-DLL3 agent is to be administered in a first cycle wherein (i) the anti-DLL3 agent is to be administered at a dose of from 1 mg to 200 mg by continuous intravenous infusion over a period of 2 days to 7 days, and (ii) after the continuous intravenous infusion, the anti-DLL3 agent is to be administered by a bolus intravenous infusion on day 8, day 15, or both day 8 and day 15, and

b) the anti-DLL3 agent is to be administered according to any one of i) to iii) below:

i) one or more subsequent doses of the anti-DLL3 agent is to be administered at a dose of from 10 mg to 100 mg starting on day 29 and once every two weeks thereafter;

ii) one or more subsequent doses of the anti-DLL3 agent is to be administered at a dose of from 10 mg to 100 mg starting on day 22 and twice every three weeks thereafter; and

iii) one or more subsequent doses of the anti-DLL3 agent is to be administered at a dose of from 20 mg to 200 mg starting on day 22 and thereafter once every three weeks.

10. The use of claim 9, wherein a) the anti-DLL3 agent is to be administered at a dose of from 30 mg to 100 mg by continuous intravenous infusion over a period of 2 days, 3 days, 5 days or 7 days.

11. The use of claim 9 or 10, wherein a) the anti-DLL3 agent is to be administered at a dose of 30 mg, 50 mg, or 100 mg by continuous intravenous infusion over a period of 2 days, 3 days, 5 days or 7 days.

12. The use of any one of claims 9-11, wherein a) the anti-DLL3 agent is to be administered at a dose of 30 mg, 50 mg or 100 mg by continuous intravenous infusion over a period of 3 days, 5 days or 7 days.

13. The use of claim 12, wherein a) the anti-DLL3 agent is administered at a dose of 30 mg or 100 mg by continuous intravenous infusion over a period of 3 days.

14. Use of an anti-DLL3 agent comprising the amino acid sequence of SEQ ID NOs: 13 and 23 and an anti-PD-L1 antibody in the manufacture of a medicament for combination therapy for treating DLL3-positive cancer, wherein the anti-DLL3 agent is to be administered according to any one of a) to c) below:

a) the anti-DLL3 agent is to be administered at a dose of from 10 mg to 100 mg once every two weeks;

b) the anti-DLL3 agent is to be administered at a dose of from 10 mg to 100 mg twice every three weeks; and

c) the anti-DLL3 agent is to be administered at a dose of from 20 mg to 200 mg once every three weeks;

optionally wherein the medicament is to be administered in conjunction with one or more therapeutic agents.

15. The use of claim 14, wherein the anti-DLL3 agent is to be administered at a dose of from 10 mg to 100 mg once every two weeks.

16. The use of claim 15, wherein the anti-DLL3 agent is to be administered at a dose of 10 mg, 30 mg, 50 mg, or 100 mg once every two weeks.

17. The use of claim 15 or 16, wherein the anti-DLL3 agent is to be administered on day 1 and day 15 of a 28-day cycle.

18. The use of claim 14, wherein the anti-DLL3 agent is to be administered at a dose of from 10 mg to 100 mg twice every three weeks.

19. The use of claim 18, wherein the anti-DLL3 agent is to be administered at a dose of 10 mg, 30 mg, or 100 mg, twice every three weeks.

20. The use of claim 18 or 19, wherein the anti-DLL3 agent is to be administered on day 1 and day 8 of a 21-day cycle.

21. The use of claim 14, wherein the anti-DLL3 agent is to be administered at a dose of from 20 mg to 100 mg once every three weeks.

22. The use of claim 14, wherein the anti-DLL3 agent is to be administered at a dose of from 100 mg to 200 mg once every three weeks.

23. The use of claim 21 or 22, wherein the anti-DLL3 agent is to be administered at a dose of 20 mg, 60 mg, 100 mg, or 200 mg once every three weeks.

24. The use of any one of claims 21-23, wherein the anti-DLL3 agent is to be administered on day 1 of a 21-day cycle.

25. The use of any one of claims 14-24, wherein prior to any one of a) to c), the anti-DLL3 agent is to be administered in a 21-day cycle according to the following regimen: a first dose of 0 mg or 1 mg on day 1, a second dose of from 1 mg to 100 mg on day 8, and a third dose of from 10 mg to 200 mg on day 15.

26. The use of claim 25, wherein the first dose is 1 mg on day 1, the second dose is from 10 mg to 100 mg on day 8, and the third dose is from 10 mg to 100 mg on day 15.

27. The use of claim 25, wherein the first dose is 1 mg on day 1, the second dose is from 10 to 100 mg on day 8, and the third dose is from 20 to 200 on day 15.

28. The use of any one of claims 22-24, wherein prior to the once every three week administration, the anti-DLL3 agent is to be administered according to the following regimen in a 21-day cycle:

(i) a first dose of 1 mg on day 1, a second dose of from 10 mg to 100 mg on day 8; or

(ii) a first dose of 1 mg on day 8, a second dose of from 10 mg to 100 mg on day 15,

wherein the 21-day cycle is the first cycle the anti-DLL3 is administered to the subject.

29. The use of claim 28, wherein the second dose in (i) or (ii) is 20 mg.

30. The method of any one of claims 14-29, wherein the anti-PD-L1 antibody is a PD-L1 blocking antibody.

31. The use of claim 30, wherein the anti-PD-L1 antibody is atezolizumab or durvalumab.

32. The use of any one of claims 14-31, wherein the one or more chemotherapeutic agents comprise a platinum-based chemotherapeutic agent, etoposide, or both.

33. The use of claim 32, wherein the platinum-based chemotherapeutic agent is carboplatin or cisplatin.

34. The use of any one of claims 14-33, wherein the anti-DLL3 agent is administered after the administration of the anti-PD-L1 antibody and the one or more chemotherapeutic agents when given on the same day.

35. Use of an anti-DLL3 agent comprising the amino acid sequence of SEQ ID NOs: 13 and 23, and an alkylating agent in the manufacture of a medicament for combination therapy for treating DLL3-positive cancer, wherein the anti-DLL3 agent is to be administered to the subject at a dose of from 10 mg to 200 mg once every three weeks.

36. The use of claim 35, wherein the anti-DLL3 agent is to be administered at a dose of from 10 mg to 100 mg once every three weeks.

37. The use of claim 36, wherein the anti-DLL3 agent is to be administered at a dose of from 100 mg to 200 mg once every three weeks.

38. The use of any one of claims 35-37, wherein the anti-DLL3 agent is to be administered at a dose of 10 mg, 20 mg, 60 mg, 100 mg, or 200 mg.

39. The use of any one of claims 35-38, wherein the anti-DLL3 agent is to be administered on day 1 of a 21-day cycle.

40. Use of an anti-DLL3 agent comprising the amino acid sequence of SEQ ID NOs: 13 and 23, and an alkylating agent in the manufacture of a medicament for combination therapy for treating DLL3-positive cancer, wherein the anti-DLL3 agent is to be administered to the subject according to the following: a first dose of 0 mg or 1 mg on day 1, a second dose of from 10 mg to

100 mg on day 8, a third dose of from 10 mg to 200 mg on day 15, and one or more subsequent doses of from 10 mg to 200 mg starting on day 22 and once every three weeks thereafter.

41. The use of claim 40, wherein the first dose is 1 mg, the second dose is from 10 mg to 100 mg, the third dose is from 10 mg to 200 mg, and the one or more subsequent doses are the same and are the same as the third dose.

42. The use of claim 40, wherein the first dose is 1 mg, the second dose is 20 mg, 60 mg, or 100 mg, the third dose is 20 mg, 60 mg, or 200 mg, and the one or more subsequent doses are the same and are each 20 mg, 60 mg or 200 mg.

43. The use of any one of claims 40-42, wherein the one or more subsequent doses are to be administered on day 1 of a 21-day cycle.

44. The use of any one of claims 35-43, wherein the alkylating agent is a platinum-based agent.

45. The use of claim 44, wherein the platinum-based agent is lurbinectedin.

46. The use of claim 45, wherein lurbinectedin is to be administered at a dose of from 2.0 $mg/m^2$ to 3.2 $mg/m^2$ once every three weeks.

47. The use of any one of claims 35-46, wherein the anti-DLL3 agent is administered after the administration of alkylating agent when given on the same day.

48. The useof any one of claims 1-47, wherein the anti-DLL3 agent comprises the amino acid sequence of SEQ ID NO: 14, 27 or 32.

49. The use of any one of claims 1-48, further comprises one or more additional therapeutic agent to be administered to the subject.

50. The use of claim 49, wherein the one or more additional therapeutic agent is a corticosteroid, saline, or an anti-IL6 antibody.

51. The use of claim 50, wherein the corticosteroid is dexamethasone.

52. The use of any one of claims 49-51, wherein the one or more additional therapeutic agent is to be administered in cycle 1 wherein the anti-DLL3 agent is to be administered.

53. The use of any one of claims 1-52, wherein the cancer is small cell lung cancer (SCLC).

54. The use of any one of claims 1-53, wherein the cancer is relapsed/refractory SCLC (RR SCLC) or extensive disease SCLC (ED SCLC).

55. The use of any one of claims 1-54, wherein the subject is a human.

56. The use of claim 55, wherein the subject had at least one prior treatment of the cancer and relapsed.

57. The use of claim 56, wherein the least one prior treatment of the cancer is platinum chemotherapy, etoposide, and optionally an anti-PD-L1 antibody.

58. The use of claim 55, wherein the subject had no prior systemic treatment of the cancer.

59. The use of any one of claims 1-58, wherein the anti-DLL3 agent is tarlatamab.

60. Use of an anti-DLL3 agent comprising the amino acid sequence of SEQ ID NOs: 13 and 23 in the manufacture of a first medicament and use of an anti-PD-L1 antibody in the manufacture of a second medicament, wherein the first and second medicament are to be used in combination therapy for treating DLL3-positve cancer, wherein the anti-DLL3 agent is to be administered according to any one of a) to c) below:

a) the anti-DLL3 agent at is to be administered a dose of from 10 mg to 100 mg once every two weeks;

b) the anti-DLL3 agent is to be administered at a dose of from 10 mg to 100 mg twice every three weeks; and

c) the anti-DLL3 agent is to be administered at a dose of from 20 mg to 200 mg once every three weeks;

optionally wherein the medicaments are to be administered in conjunction with one or more chemotherapeutic agents.

61. Use of an anti-DLL3 agent comprising the amino acid sequence of SEQ ID NOs: 13 and 23 in the manufacture of a medicament for use in combinatorial therapy for treating DLL3-positive cancer, wherein the medicament is to be administered in combination with an anti-PD-

L1 antibody to a subject in need thereof, wherein the anti-DLL3 agent is to be administered according to any one of a) to c) below:

a) the anti-DLL3 agent at is to be administered a dose of from 10 mg to 100 mg once every two weeks;

b) the anti-DLL3 agent is to be administered at a dose of from 10 mg to 100 mg twice every three weeks; and

c) the anti-DLL3 agent is to be administered at a dose of from 20 mg to 200 mg once every three weeks;

optionally wherein the composition is to be administered in conjunction with one or more chemotherapeutic agents.

62. Use of an anti-PD-L1 antibody in the manufacture of a medicament for use in combinatorial therapy for treating DLL3-positive cancer, wherein the medicament is to be administered in combination with an anti-DLL3 agent comprising the amino acid sequence of SEQ ID NOs: 13 and 23, wherein the anti-DLL3 agent is to be administered according to any one of a) to c) below:

a) the anti-DLL3 agent is to be administered at a dose of from 10 mg to 100 mg once every two weeks;

b) the anti-DLL3 agent is to be administered at a dose of from 10 mg to 100 mg twice every three weeks; and

c) the anti-DLL3 agent is to be administered at a dose of from 20 mg to 200 mg once every three weeks;

optionally wherein the medicament is to be administered in conjunction with one or more chemotherapeutic agents.

63. Use of an anti-DLL3 agent comprising the amino acid sequence of SEQ ID NOs: 13 and 23 in the manufacture of a first medicament and use of an alkylating agent in the manufacture of a second medicament, wherein the first and second medicament are to be used in combination therapy for treating DLL3-positve cancer, wherein the anti-DLL3 agent is to be administered to the subject at a dose of from 10 mg to 200 mg once every three weeks.

64. Use of an anti-DLL3 agent comprising the amino acid sequence of SEQ ID NOs: 13 and 23 in the manufacture of a medicament for use in combinatorial therapy for treating DLL3-positive cancer, wherein the medicament is to be administered in combination with an alkylating agent to a subject in need thereof, wherein the anti-DLL3 agent is to be administered to the subject at a dose of from 10 mg to 200 mg once every three weeks.

65. Use of an alkylating agent in the manufacture of a medicament for use in combinatorial therapy for treating DLL3-positive cancer, wherein the medicament is to be administered in combination with an anti-DLL3 agent comprising the amino acid sequence of SEQ ID NOs: 13 and 23 to a subject in need thereof, wherein the anti-DLL3 agent is to be administered to the subject at a dose of from 10 mg to 200 mg once every three weeks.

66. Use of an anti-DLL3 agent comprising the amino acid sequence of SEQ ID NOs: 13 and 23 in the manufacture of a first medicament and use of an alkylating agent in the manufacture of a second medicament, wherein the first and second medicament are to be used in combination therapy for treating DLL3-positve cancer, wherein the anti-DLL3 agent is to be administered to the subject according to the following: a first dose of 0 mg or 1 mg on day 1, a second dose of from 10 mg to 100 mg on day 8, a third dose of from 10 mg to 200 mg on day 15, and one or more subsequent doses of from 10 mg to 200 mg starting on day 22 and once every three weeks thereafter.

67. Use of an anti-DLL3 agent comprising the amino acid sequence of SEQ ID NOs: 13 and 23 in the manufacture of a medicament for use in combinatorial therapy, wherein the medicament is to be administered in combination with an alkylating agent to a subject in need thereof, wherein the anti-DLL3 agent is to be administered to the subject according to the following: a first dose of 0 mg or 1 mg on day 1, a second dose of from 10 mg to 100 mg on day 8, a third dose of from 10 mg to 200 mg on day 15, and one or more subsequent doses of from 10 mg to 200 mg starting on day 22 and once every three weeks thereafter.

68. Use of an alkylating agent in the manufacture of a medicament for use in combinatorial therapy for treating DLL3-positive cancer, wherein the medicament is to be administered in combination with an anti-DLL3 agent comprising the amino acid sequence of SEQ ID NOs: 13

and 23 to a subject in need thereof, wherein the anti-DLL3 agent is to be administered to the subject according to the following: a first dose of 0 mg or 1 mg on day 1, a second dose of from 10 mg to 100 mg on day 8, a third dose of from 10 mg to 200 mg on day 15, and one or more subsequent doses of from 10 mg to 200 mg starting on day 22 and once every three weeks thereafter.